All In Biotech

Drug Trial Radar · NCT05246137

A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Safety and Immunogenicity of a Booster Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Vaccinated Against COVID-19.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,661

Actual

Start

Feb 3, 2022

Primary completion

Mar 3, 2023

Study completion Mar 3, 2023

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
First posted
Feb 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Conditions

  • SARS-CoV-2 Infection

Interventions

  • COVID-19 Vaccine 40 ug/doseBiological

    Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)Time frame: Day 7
  2. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)Time frame: Day 28
  3. Incidence of Serious Adverse Events (Safety and tolerability) (SAE)Time frame: Day 365
  4. Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).Time frame: Day 365
  5. Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)Time frame: Day 365
  6. Incidence of Adverse Events in laboratory parameters (Safety and tolerability)Time frame: Day 365

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital de Niguarda

    Milan, Milano, Italy

  • Hospital HM Delfos

    Barcelona, Barcelona, Spain

  • Hospital Quironsalud Barcelona

    Barcelona, Barcelona, Spain

  • Hospital de Mollet

    Mollet del Vallès, Barcelona, Spain

  • Hospital Germans Trias I Pujol

    Badalona, BARCELONA, Spain

  • Hospital Vall Hebron

    Barcelona, BARCELONA, Spain

  • Hospital Universitari Dr. Josep Trueta

    Girona, Girona, Spain

  • Hospital Gregorio Marañón

    Madrid, Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital HM Sanchinarro

    Madrid, Madrid, Spain

  • Hospital Quironsalud Madrid

    Madrid, Madrid, Spain

  • Hospital HM Montepríncipe

    Madrid, Madrid, Spain

  • Hospital Principe de Asturias

    Meco, Madrid, Spain

  • Hospital HM Puerta del Sur

    Móstoles, Madrid, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Málaga, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain

  • Hospital de Cruces

    Barakaldo, VIZCAYA, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.